Combination therapy of recombinant human alpha 2 interferon and acyclovir in the treatment of herpes simplex keratitis.
No statistical difference was found in both partial and complete healing time in acute epithelial herpetic keratitis between the ACV-recombinant human alpha 2 IFN (both "eyedrops" and "eyerods") and Buffy coat human leucocyte alpha IFN. A highly significant difference was found in both partial and complete healing time between the ACV-IFN combination versus the ACV-Placebo combination. The combination of ACV and recombinant human alpha 2 arg IFN is a potent anti-herpetic treatment.
D000212:Acyclovir / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004274:DNA, Recombinant; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D007635:Keratitis, Dendritic / Q000188:drug therapy / Q000628:therapy*; D011994:Recombinant Proteins; D013997:Time Factors
D004274:DNA, Recombinant; D007370:Interferon Type I; D011994:Recombinant Proteins; D000212:Acyclovir